US20100298209A1 - Compounds for preventing or treating a viral infection - Google Patents

Compounds for preventing or treating a viral infection Download PDF

Info

Publication number
US20100298209A1
US20100298209A1 US12/740,790 US74079008A US2010298209A1 US 20100298209 A1 US20100298209 A1 US 20100298209A1 US 74079008 A US74079008 A US 74079008A US 2010298209 A1 US2010298209 A1 US 2010298209A1
Authority
US
United States
Prior art keywords
virus
compound
viral
hiv
genus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/740,790
Other languages
English (en)
Inventor
Jérôme Estaquier
Mireille Laforge
Anna Senik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), INSTITUT PASTEUR reassignment INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ESTAQUIER, JEROME, LAFORGE, MIREILLE, SENIK, ANNA
Publication of US20100298209A1 publication Critical patent/US20100298209A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention falls within the field of viral infections and the development of novel medicaments for the prophylaxis and/or treatment of viral infections, especially retroviral, in particular lentiviral, infections, for example human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections.
  • retroviral in particular lentiviral, infections, for example human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections.
  • HIV human immunodeficiency virus
  • SIV simian immunodeficiency virus
  • the invention relates to a compound of structure I: A-B-C, for use in the prophylaxis and/or treatment of a viral infection, in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-type group, B is a single amino acid or a peptide or polypeptide having a given amino acid sequence, C is an O-phenoxy group and the symbol “-” indicates that the entities A, B and C are chemically bonded within the compound I.
  • the invention relates more particularly to the compound Q-VD-OPh (N-(2(quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone), for use in the prophylaxis and/or treatment of a viral infection, in particular for preventing and/or inhibiting viral replication.
  • Q-VD-OPh N-(2(quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone
  • the invention relates also to the use of said compound of structure I, and especially of the compound Q-VD-OPh, in the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of a viral infection and, in particular, for preventing and/or inhibiting viral replication.
  • the present invention relates also to a novel antiviral composition and to a novel combination (or kit) of suitable compounds for use in the prophylaxis and/or treatment of a viral infection, which comprise, consist essentially or consist of:
  • the present invention relates to a method for preventing or treating a viral infection in an animal or human.
  • Viral replication is the process by which a virus (DNA or RNA) hijacks and uses the machinery of the cell it infects to multiply.
  • the main steps of the replication of retroviruses, and in particular of HIV viruses are as follows: (1) fixing of the virus to the surface of a cell of an animal or human organism by recognition between virus surface proteins and receptors at the surface of said cell (for example the CD4 receptor); (2) penetration of the virus into the cell cytoplasm by fusion of the virus envelope with the cell membrane; (3) decapsidation of the virus (the virus separates from the matrix and from the capsid, which releases the two copies of the viral genome); (4) reverse transcription of the viral RNAs in the form of a proviral DNA by virtue of reverse transcriptase (viral enzyme); (5) migration of the proviral DNA into the nucleus and integration of that DNA into the DNA of the host cell under the effect of integrase (viral enzyme); (6) transcription of the DNA of the cell into genomic RNA (unspliced messenger RNA
  • HIV virus has developed various strategies for escaping the immune system and facilitating their dissemination during the infection.
  • the HIV virus has the particular feature of causing the complete breakdown of the immune system by attacking a key cell of the immune system, the auxiliary T lymphocyte (CD4+ T lymphocyte), which expresses at its surface the CD4 molecule, a specific HIV receptor.
  • CD4+ T lymphocyte auxiliary T lymphocyte
  • the monocytes-macrophages, the dendritic cells, the Langerhans cells and the cerebral microglial cells are likewise targets of HIV.
  • lymphocytes The gradual disappearance of the lymphocytes leads to a lack of control of viral replication by the immune system, to the destruction of the lymphoid organs, where the immune response takes place, and to the onset of acquired immunodeficiency syndrome (AIDS), with the occurrence of severe opportunistic infections.
  • AIDS acquired immunodeficiency syndrome
  • the HIV viral particle is composed of a nucleocapsid which contains the single-stranded RNA dimer of positive polarity associated with the nucleocapsid protein, lysine tRNAs and the viral enzymes (reverse transcriptase, protease and integrase).
  • the nucleocapsid is enclosed in a coat of matrix proteins which is covered by a lipid membrane borrowed from the host cell during budding of the viral particle.
  • the membrane is provided with spikes composed of envelope glycoprotein oligomers.
  • the step of conversion of the RNA into bicatenary DNA during the viral cycle under the action of a viral enzyme, reverse transcriptase is the main characteristic of the retroviruses.
  • the viral genes gag, pol and env are retained in all retroviruses. All the products derived therefrom are present in the viral particle. They come from the cleavage of precursor polyproteins. The genes gag and env code for structural proteins, and the gene pol codes for numerous enzymatic proteins.
  • the Gag proteins are obtained from the cleavage of the polyprotein Pr55gag by viral protease. The cleavage releases the matrix protein, the capsid protein, the nucleocapsid protein, as well as a 6 kDa protein. Recent works suggest that these processes play an essential role in the genesis of infectious viral particles (Sticht et al., 2005; Ternois et al., 2005). These recent works have made it possible to generate, for the first time, an HIV assembly inhibitor.
  • the envelope precursor gp160 is cleaved into a surface glycoprotein gp120 (gp130 for SIVmac) and a transmembrane protein gp41 derived from the C-terminal region of the precursor. During its maturation, the precursor gp160 is glycosylated and then cleaved by a cell protease in the Golgi apparatus and then exported to the plasmic membrane. The two glycoproteins derived from the cleavage remain associated by non-covalent bonds. They form heteromers of envelope glycoproteins, which combine in oligomers to form the spikes of the virion.
  • the gene pol codes for three enzyme proteins: protease, reverse transcriptase and integrase. They are derived from the cleavage of the polyprotein Gag-Pol (Pr160 gag-pol) during the morphogenesis of the virion. Dimerization in the cell of the polyprotein Gag-Pol reveals the protease activity coded for by the 5′-region of pol. The mature form of the protease, released by autocatalytic cleavage, remains in the dimeric form p11 /p11 and is then able to cleave other sites present on the polyproteins Pr160gag-pol and Pr55gag.
  • Reverse transcriptase is derived from the cleavage of the polyprotein Pr160gag-pol in two steps by the viral protease during the assembly of the viral particle.
  • integrase Located in the C-terminal position of the Pol region of the polyprotein Gag-Pol, integrase is released in the form of a 32 kDa protein under the action of the viral protease. Its oligomerization is required both for its incorporation into the viral particle and to exert its activity of integrating linear double-stranded viral DNA into the cell genome.
  • HIV therapy known as highly active anti-retroviral therapy or “HAART” today includes one or more HIV protease inhibitors. This therapy leads to inhibition of viral replication, an increase in the number of CD4 T lymphocytes and an indisputable clinical improvement.
  • Apoptosis or programmed cell death or even cell suicide is the process by which cells trigger their self-destruction in response to a signal (pro-apoptotic signal).
  • pro-apoptotic signal The environment, interactions between cells, the absence of nourishment for the cell, infection by a pathogenic agent, are a few examples of pro-apoptotic signals.
  • Apoptosis is a morphologically and biochemically defined form of cell death which is characterized in vivo by the absence of an inflammatory response, the activation of caspases and the cleavage of numerous proteins, fragmentation of the DNA, condensation of chromatin, cell contraction and the disassembly of cell structures to form vesicles incorporated into the membrane (apoptotic bodies). In vivo, this process culminates in the phagocytosis of apoptotic bodies by other cells.
  • Precocious apoptosis of a cell infected by a virus can constitute a defence mechanism of the host; it allows the number of viral particles released to be limited by interrupting viral replication.
  • the cell endonucleases produced during apoptosis can act on the viral DNA and inhibit the synthesis of viral, structural and regulatory proteins and the formation of infectious viral particles, thus limiting the dissemination of virions in the host.
  • viruses act on the regulation of the apoptotic intracellular signals, either in order to keep themselves alive or to keep the infected cell viable or to prevent the cell from being attacked by the effector cells of the immune system, and thus increase the efficacy of viral replication and permit greater production of virions.
  • the majority of viruses have one or more genes permitting the synthesis of proteins whose effect is to suppress, at different stages, apoptosis of the cells they infect (antiapoptotic proteins). By retarding or inhibiting the death of the host cell, viruses promote the survival of the cell they infect and therefore their own survival, to the extent of promoting the occurrence of cancers in some cases.
  • viruses have also developed strategies for causing the death of the cells they infect, leading to cell deficiencies, in particular immune deficiencies (such as those associated with AIDS), neuronal deficiencies (such as those associated with rabies) and epithelial deficiencies (such as those associated with haemorrhagic fevers).
  • immune deficiencies such as those associated with AIDS
  • neuronal deficiencies such as those associated with rabies
  • epithelial deficiencies such as those associated with haemorrhagic fevers.
  • Some viruses are additionally capable of inducing apoptosis at a late phase of the infection, which allows the virions to propagate into the neighbouring cells while escaping the inflammatory and immune response of the host (Everett & McFadden, 1999).
  • the apoptotic processes induced by viruses are at the origin of cell disturbances which influence the clinical evolution of viral infections.
  • Infection by HIV is a very representative example.
  • Infection by HIV-1 is accompanied by abnormal induction of apoptosis in the adult T lymphocytes, the thymocytes and the haematopoietic precursors.
  • excess apoptosis affects all the lymphocyte populations (CD4 T, CD8 T and B), and the degree of apoptosis correlates with the evolution of the disease (Gougeon et al., 1996).
  • lymphocyte apoptosis is abnormally elevated in the lymphatic ganglions (Amendola et al., 1996), which constitute the main replication sites of the virus.
  • lymphatic ganglions Amendola et al., 1996)
  • the majority of the T cells that undergo apoptosis are not infected by the virus (“bystander” effect) (Finkel et al., 1995).
  • HIV The regulation of apoptosis by HIV is all the more complex because the virus is capable of manipulating the apoptotic machinery to its advantage by acting as both an activator and a repressor of apoptosis. HIV has in fact also developed mechanisms of inhibiting apoptosis in order to escape the host's immune system.
  • lentiviruses in particular feline immunodeficiency virus (FIV) and some strains of simian immunodeficiency virus (SIV), are also capable of inducing apoptosis and causing an immune deficiency syndrome in their natural host. Accordingly, within the scope of a study of different models of chronic lentiviral infections in primates, the inventors of the present invention have previously shown that the CD4+ T lymphocytes are abnormally sensitive to apoptosis in the rhesus macaque infected by the pathogenic strain SIVmac251 (Hurtrel et al., 2005).
  • caspases from the English cysteinyl aspartate-specific proteases or cysteine aspartate proteases. Caspases have been found in many organisms, ranging from C. elegans to humans. To date, more than about twelve caspases have been identified. These intracellular enzymes have a key role in apoptosis, inflammation, activation and cell differentiation.
  • caspases are expressed in the form of proenzymes which undergo proteolytic maturation. These precursors are expressed constitutively in the cell cytoplasm.
  • the procaspases (from 30 to 50 kD) contain three domains: an N-terminal prodomain, a large subunit (about 20 kD) and a small subunit (about 10 kD).
  • Activation involves proteolytic cleavage between the domains, followed by the association of the large and the small subunit, each of which contributes to the amino acids of the active site, to form a heterodimer.
  • the active mature enzymes function in the form of a tetramer composed of two heterodimers.
  • the N-terminal domain of the caspases whose length (from 23 to 216 amino acids) and sequence vary greatly, is involved in the regulation of those enzymes.
  • the function of the caspases is determined by their substrate specificity, the length of their prodomain and the sequence of the prodomain.
  • the caspases can be divided into three groups: the inflammatory caspases (group I), the initiator (or regulatory) caspases (group II) and the effector (or executor) caspases (group III) (Lavrik et al., 2005).
  • the long prodomain (more than 100 amino acids) of the initiator caspases and of the inflammatory caspases acts as an apoptotic or proinflammatory signal integrator.
  • the inflammatory caspases include caspase-1, -4, -5, -11, -12, -13 and -14.
  • the initiator caspases include caspase-2, -8, -9 and -10. They are located upstream of the apoptotic signalling cascades and are activated by autoproteolytic mechanisms in response to proapoptotic signals. They then cleave and activate the effector caspases, which are located downstream of the signalling cascades, permitting amplification of the apoptotic signal.
  • the effector caspases include caspase-3, -6 and -7.
  • proteins inactivated by the action of these caspases include proteins which protect the cells from apoptosis (antiapoptotic proteins), such as proteins of the Bcl-2 family.
  • the caspases the catalytic domain of which includes a cysteine residue (C), cleave their protein substrate(s) at specific consensus sites containing an aspartic residue which are located in the carboxy-terminal part of the substrate. They exhibit substrate recognition motifs and highly conserved catalytic motifs (Cryns et al., 1998).
  • caspase inhibitors include a single amino acid or a generally di- to tetra-peptide amino acid sequence, which is optionally O-methylated and which is conjugated to a carboxy-terminal group such as fluoromethyl ketone (fmk), chloromethyl ketone (cmk), an aldehyde group (CHO) or a difluorophenoxy group (OPh).
  • fluoromethyl ketone fmk
  • chloromethyl ketone cmk
  • CHO aldehyde group
  • Oh difluorophenoxy group
  • caspase inhibitors are capable of penetrating the cells and binding irreversibly (with the exception of inhibitors having an aldehyde group, whose binding is reversible) to the active site of the caspases. They accordingly act as proteolytic decoys by blocking proteolytic caspase cleavage, which is required for activation of said caspases and the production of an active truncated caspase.
  • Inhibitors having a carboxy-terminal group fmk or OPh have been formulated for in vivo and in vitro applications.
  • Two of the most widely used caspase peptide inhibitors are the inhibitors Boc-D-fmk (tert-butyloxycarbonyl-Asp(O-methyl)-fluoromethyl ketone; Enzyme Systems Products, CalBiochem or R&D Systems) and z-VAD-fmk (N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone; Enzyme Systems Products, CalBiochem or R&D Systems).
  • Boc (tert-butyloxycarbonyl) and z (N-benzyloxycarbonyl) groups serve to block the amino acid sequences D (Asp) or VAD (Val-Ala-Asp), while the fluoromethyl ketone group in the carboxy-terminal position facilitates membrane permeability. It has been shown that inhibition of the activation of caspases by such inhibitors prevents the appearance of the morphological modifications which are characteristic of apoptosis (Chinnaiyan et al., 1997).
  • a more recently developed caspase inhibitor, Q-VD-OPh N-(2(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone; Enzyme Systems Products, CalBiochem or R&D Systems
  • Q-VD-OPh N-(2(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone; Enzyme Systems Products, CalBiochem or R&D Systems
  • fmk fluoromethyl ketone
  • the inhibitor Q-VD-OPh has been found to be functional in vitro, in different cell types, and in vivo, in animal models, in particular in the mouse and the rat. Moreover, it has been shown that it inhibits various caspases, in particular caspase-1, -3, -8, -9, -10 and -12, with IC50 values ranging from 25 to 400 nM. Furthermore, Q-VD-OPh, like the inhibitors ZVAD-fmk and Boc-D-fmk, inhibits apoptosis in a dose-dependent manner (Caserta et al., 2003).
  • the inhibitor z-VAD-fmk is capable of stimulating endogenous viral replication in activated PBMCs derived from patients who are HIV-1-positive but are asymptomatic (Chinnaiyan et al., 1997).
  • apoptosis might help the host to limit propagation of the virus and that, consequently, strategies aimed at inhibiting cell death might have deleterious consequences for the infected host and might, in particular, contribute towards increasing the viral load of an HIV-positive individual. This would be in agreement with the fact that many viruses produce proteins that inhibit cell death in the host (for example the CrmA protein produced by the vaccinia virus).
  • the present invention appears surprising.
  • the results presented in the present application in fact show that the compound Q-VD-OPh not only permits inhibition of the apoptotic phenotype (caspase inhibition, DNA condensation and fragmentation) of the HIV-infected cells, but also inhibition of their death and especially inhibition of viral replication.
  • the invention accordingly relates to the compound Q-VD-OPh or a derivative thereof and, more generally, to a structure I as defined in the present application, for use as a medicament, in particular as an antiviral agent and more particularly as an antiretroviral agent.
  • Said compound is used in particular for the prophylaxis and/or treatment of a viral infection, in particular in an animal or human, and more particularly for inhibiting viral replication in an animal or human infected by a virus.
  • the invention relates also to the use of at least one compound of structure I, in particular to the use of the compound Q-VD-OPh, in the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of a viral infection, in particular in an animal or human, and more particularly for preventing and/or inhibiting viral replication in an animal or human infected by a virus.
  • Said compound I comprises or consists of at least one amino acid, that is to say a single amino acid or a plurality of amino acids in the form of a peptide or polypeptide having a given amino acid sequence, the carboxyl group of said single amino acid or the C-terminal portion of said peptide or polypeptide being bonded to an O-phenoxy group and the amine group of said single amino acid or the N-terminal end of said peptide or polypeptide being bonded to a quinoline or quinoline-type group. It has been shown that the use of carboxy-terminal O-phenoxy groups enables the efficacy of caspase inhibitors to be improved and their toxicity to be reduced (Caserta et al., 2003).
  • the compound of structure I is of the type A-B-C, A being a quinoline or quinoline-type group, B being a single amino acid or a peptide or polypeptide having a given amino acid sequence, and C being an O-phenoxy group, the symbol “-” indicating that the entities A, B and C are chemically bonded within the compound I.
  • the groups A, B and C are bonded (or fused) covalently, for example by way of peptide bonds.
  • quinoline as used in the present application includes the structure of the 1-aza-naphthalene type.
  • quinoline-type as used in the present application includes structures having a carbonyl group fixed in the 2- or 3-position to the quinoline, in particular to the 1-aza-naphthalene structure, for example quininic acid. This expression also includes the melatonin structure and similar structures. According to a particular embodiment, said quinoline-type group is the group 2-quinolylcarbonyl.
  • the quinoline group is replaced by the indole structure.
  • the expression “quinoline-type” then includes structures having a carbonyl group fixed in the 2- or 3-position to the indole structure.
  • the structure I is:
  • alkyl refers to alkyl groups having preferably from approximately 1 to 20 carbon atoms, more preferably from approximately 1 to 10 carbon atoms, for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.
  • the term includes all the configurations of the alkyl groups.
  • said alkyl group is a methyl group or an ethyl group.
  • alkoxy or “alkoxyl” denotes the group —O-alkyl having preferably from approximately 1 to 20 carbon atoms, more preferably from approximately 1 to 10 carbon atoms, for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. These terms include all the configurations of the alkyl groups. According to a particular embodiment, said alkyl group is a methyl group or an ethyl group.
  • aryl includes especially the groups phenyl, naphthalyl and similar structures.
  • peptide or polypeptide having a given amino acid sequence denotes a chain of several (at least two) successive amino acids forming the structure of a peptide (that is to say a chain of less than 20 amino acids) or of a polypeptide (that is to say a chain of more than 20 amino acids).
  • the peptide has a di-, tri- or tetra-peptide sequence, that is to say a sequence composed of two, three or four successive amino acids.
  • the single amino acid is an aspartic acid (D or Asp) or said peptide or polypeptide comprises at least one aspartic acid.
  • the compound of structure I comprises an aspartic acid (D) and a valine (V or Val).
  • D aspartic acid
  • V or Val valine
  • said peptide or polypeptide has a dipeptide sequence
  • its sequence can be Valine-Aspartic acid (VD).
  • VXD Valine-X-Aspartic acid
  • VD Valine-Aspartic acid-Alanine
  • VAD Valine-Alanine-Aspartic acid
  • part B of the compound of structure I comprises or consists of the chain of amino acids Valine-Aspartic acid (VD).
  • VD Valine-Aspartic acid
  • said chain can be followed and/or preceded by one or more (two, three, four, five or more than five) other amino acid(s), which can be of any type.
  • the compound of structure I is A-VD-C, in which A and C have any one of the definitions given in the present application, and more particularly the compound Q-VD-OPh.
  • the invention does not relate to the compound Q-DEVD-OPH and/or to the compound Q-LEDH-OPH and/or to the compound Q-IETD-OPH, taken as such.
  • the single amino acid or at least one of the amino acids of the peptide or polypeptide of the compound of structure I is O-methylated.
  • said compound can in particular be O-methylated on the aspartic acid or on at least one of its aspartic acids.
  • the single amino acid or the amino acid sequence of the peptide or polypeptide of the compound of structure I is not O-methylated.
  • the absence of O-methylation is supposed to reduce the hydrophobicity of the peptide and facilitate its use in an aqueous medium.
  • R1 and/or R2 is(are) hydrogen.
  • R3 and/or R4 is(are) a fluoro.
  • the compound of structure I according to the invention is a protease inhibitor, in particular a caspase inhibitor.
  • cystpase denotes any cysteine protease as defined above.
  • Protease inhibitor or “caspase inhibitor” is understood as meaning any compound which is capable of inhibiting the activation of at least one protease or the activation of at least one caspase, respectively, in particular any compound which prevents or inhibits the process of proteolytic cleavage which allows said protease or caspase to be obtained in active form.
  • said caspase inhibitor prevents or inhibits the production of apoptogenic forms of the caspase in question.
  • Demonstration of the inhibition (of the activation) of one or more protease(s) and in particular of one or more caspases can be carried out, for example, by immunotransfer (Western blot) using antibodies specific for different forms and proforms of said protease(s) or caspase(s) which are supposed to be inhibited by said inhibitor, as described in FIG. 1 and in Example B-1.
  • the inhibition of one or more protease(s) or caspase(s) can be total (in which case the active form of said protease(s) or caspase(s) is not detected) or only partial (said protease(s) or caspase(s) is(are) then detected in active form but in a reduced quantity as compared with the quantity detected in the absence of the inhibitor).
  • the compound of structure I according to the invention inhibits:
  • the compound of structure I inhibits a plurality of caspases (two, three, four or more than four caspases) of group I and/or of group II and/or of group III.
  • the compound of structure I according to the invention is a broad-spectrum inhibitor, that is to say it inhibits one or more caspase(s) from two groups selected from groups I, II and III or from the three groups I, II and III.
  • the compound of structure I according to the invention or one of the compounds of structure I according to the invention is the compound of the following formula:
  • the compound of structure I according to the invention or one of the compounds of structure I according to the invention is the O-methylated compound Q-VD-OPh (N-(2(quinolyl)valyl-O-methyl-aspartyl-(2,6-difluorophenoxy)methyl ketone), the empirical formula of which is C27H27F2N3O6, or the non-O-methylated compound Q-VD-OPh (N-(2-(quinolyl)valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone), the empirical formula of which is C26H25F2N3O6.
  • the compound of structure I according to the invention or one of the compounds of structure I according to the invention is the compound of the following formula:
  • the compound Q-VD-OPh is preferably in O-methylated form, the non-O-methylated form generally being less stable than the O-methylated form.
  • antiviral agent and “antiretroviral agent” are understood as meaning, respectively, any agent (that is to say any active ingredient) having an antiviral or antiretroviral effect.
  • agents include in particular antiviral and in particular antiretroviral medicaments which act on at least one step of the replication of the virus.
  • said agents can allow viral replication to be prevented, reduced or inhibited.
  • the present invention relates also to a composition, in particular a pharmaceutical composition, comprising at least one compound of structure I as defined in the present application.
  • the compound according to the invention which is used in the prophylaxis and/or treatment of a viral infection, can be characterized in that it is used in the production of a composition, in particular a pharmaceutical composition (for example an antiviral composition).
  • a composition in particular a pharmaceutical composition (for example an antiviral composition).
  • said composition further comprises one or more carrier(s), diluent(s) or adjuvant(s) or a combination thereof.
  • the compound of structure I according to the invention can be administered to any animal or human likely to benefit from such administration, in particular to any animal or human infected or likely to be infected by a virus as described in the present application.
  • animal defines any non-human animal, in particular any non-human mammal, and more particularly an ape or a cat.
  • a viral infection and “infected by a virus” mean that said animal or human has been exposed to a pathogenic RNA or DNA virus and that said virus has attached itself to one or more cells of the host and has then penetrated (or is likely to penetrate) into said cell(s) and has had (or will possibly have) harmful effects for at least one cell of said animal or human.
  • a viral infection is capable of evolving into clinical signs of induced pathologies or pathologies accompanying said infection.
  • a “viral infection” within the scope of the present invention includes the earliest phases of viral contamination as well as the latest phases and the intermediate phases of viral contamination.
  • the infection evolves in several phases which may follow one another over time.
  • phases in particular are distinguished: (1) the primary infection corresponds to the phase of seroconversion which follows contamination and is (in 50 to 75% of cases) or is not accompanied by symptoms; it is followed by (2) a latent phase, then (3) a phase with minor symptoms, and finally (4) the phase of profound immunodepression or the AIDS stage, which is generally symptomatic and is generally accompanied by numerous opportunistic infections.
  • viral infection therefore also includes any clinical sign, symptom or disease that occurs in an animal or human (patient) following contamination of said animal or patient by a virus as described in the present application. Accordingly, the “viral infection” includes both contamination by said virus and the various pathologies which are the consequence of contamination by said virus.
  • the viral infections which fall within the scope of the present invention include in particular the group constituted by viral encephalitis, viral meningitis, aphthous fever, influenza, yellow fever, respiratory viral infections, infantile diarrhoea, in particular infantile diarrhoea caused by rotavirus, haemorrhagic fevers, in particular haemorrhagic fevers caused by the Ebola virus, the dengue virus and the Lassa virus, poliomyelitis, rabies, measles, rubella, varicella, smallpox, herpes zoster, genital herpes, hepatitis, especially A, B, C, D and E, SARS, leukaemia and paralysis due to HTLV-1 (human T lymphotropic virus type 1), as well as infections caused by an HIV virus, and more particularly by HIV-1 or HIV-2, or an SIV virus, which include in particular acquired immunodeficiency syndrome (AIDS).
  • AIDS acquired immunodeficiency syndrome
  • prophylaxis denotes any degree of retardation in the time of appearance of clinical signs or symptoms of the viral infection, as well as any degree of inhibition of the severity of the clinical signs or symptoms of the viral infection, including, but not being limited to, the total prevention of the viral infection.
  • the prophylactic administration of the compound of structure I according to the present invention or of a composition or combination comprising said compound can take place before said animal or human is exposed to the virus responsible for the viral infection, or at the time of exposure. Such a prophylactic administration serves to prevent and/or reduce the severity of any subsequent infection.
  • Treatment is understood as meaning the therapeutic effect produced on an animal or human by the active substances (in particular the caspase inhibitor(s) according to the invention) when they are administered to said animal or human at the time of contamination of said animal or human by the virus or after contamination.
  • the compound of structure I according to the invention or a composition or combination comprising said compound of structure I is administered to an animal or human after contamination by the virus, it can be administered during the primary infection phase, during the asymptomatic phase or after the appearance of clinical signs or symptoms of the disease. According to a particular embodiment, administration takes place within 24 or 48 hours of said animal or human being exposed to said virus, as quickly as possible.
  • treatment includes any curative effect obtained by virtue of the compound of structure I according to the invention or a composition or combination comprising said compound, and also the improvement in the clinical signs or symptoms observed in the animal or patient as well as the improvement in the condition of the animal or patient.
  • the term includes in particular the effects obtained as a consequence of inhibiting viral replication and/or inhibiting cell death induced by the virus. Accordingly, the term “treatment” covers the slowing down, reduction, interruption and stopping of the viral infection and/or of the harmful consequences of the viral infection; treatment does not necessarily require the complete removal of all the clinical signs of the viral infection and the symptoms of the disease, nor the complete elimination of the virus.
  • treatment also applies to the expression “treat an infection”.
  • the compound of structure I according to the invention or a composition or combination comprising said compound of structure I can therefore be administered to an animal or human at risk of developing a viral infection (prophylaxis) or after contamination by the virus has taken place, in particular after manifestation of the first clinical signs or symptoms of the disease, for example after proteins or antibodies specific to said virus have been detected in the blood of the animal or patient (treatment).
  • treatment is started when the patient exhibits clinical signs of immunodepression or when the level of T lymphocytes, in particular TCD4+ lymphocytes, in a sample of blood taken from the patient or animal is less than 350 per microlitre, in particular less than 200 per microlitre.
  • the compound of structure I according to the invention or a composition or combination comprising said compound of structure I is administered to an animal or human before said animal or human is exposed to said virus, during exposure to said virus or after exposure to said virus.
  • Administration after exposure to the virus can be carried out at any time but will preferably be carried out as quickly as possible after exposure, in particular within 48 hours of the animal or human being exposed to said virus.
  • viruses that fall within the scope of the present invention include DNA viruses and RNA viruses, in particular viruses responsible for cell deficiencies such as immune deficiencies (such as AIDS), neuronal deficiencies (such as rabies) or epithelial deficiencies (such as haemorrhagic fevers).
  • immune deficiencies such as AIDS
  • neuronal deficiencies such as rabies
  • epithelial deficiencies such as haemorrhagic fevers
  • said virus is a virus selected from the following families:
  • the present invention is directed in particular to the lentiviruses, in so far as they cause the degeneration of multiple organs.
  • said virus is a human retrovirus, in particular a human lentivirus, more particularly a human immunodeficiency (HIV) virus such as HIV-1 or HIV-2, and preferably HIV-1.
  • HIV human immunodeficiency
  • said virus is a simian retrovirus, in particular a simian lentivirus, and more particularly a simian immunodeficiency virus (SIV) such as the SIVmac251 or SIVmac239 virus or any other virus mentioned in Gordon et al.
  • SIV simian immunodeficiency virus
  • the compound(s) of structure I according to the invention or a composition or combination comprising the compound(s) of structure I can be used to prevent, reduce and/or inhibit viral replication in an animal or human infected by a virus as defined above.
  • viral replication includes the totality of the steps of the replication cycle of the virus, in particular the main steps of replication of the retroviruses described in the present application, including entry of the virus into the cell, integration of the viral genome into the DNA of the host cell, and viral maturation.
  • “Viral maturation” or “maturation of the viruses” denotes, in the case of the lentiviruses and in particular in the case of the HIV viruses, the process of cleavage of the Gag polyproteins, by the viral protease, into 4 structural proteins (p17, p24, p7 and p6) and the assembly of those proteins to the matrix (p17), capsid (TCD4+ p24) and nucleocapsid (p7). Following the maturation phase, the virions, which, prior to cleavage, were not mature, are infectious, that is to say ready to infect new cells.
  • the prevention or inhibition of viral replication can be either partial or total.
  • the compound(s) of structure I or a composition or combination comprising it(them) has(have) the ability to prevent, reduce and/or inhibit viral replication in vitro.
  • the compound(s) of structure I is(are) the compound Q-VD-OPH or a derivative of the compound Q-VD-OPH (for example a compound of structure I in which part B consists of the amino acid chain VD), said derivative having retained the ability of the compound Q-VD-OPH to prevent, reduce and/or inhibit viral replication in vitro.
  • the effect tested in vitro is also obtained in vivo, under appropriate use conditions.
  • the ability of the compound of structure I according to the invention or of a composition or combination comprising said compound of structure I to prevent or inhibit viral replication can be evaluated, for example, in vitro, by flow cytometry, after intracellular labelling of a viral antigen such as p24, as described in the examples below.
  • the compound of structure I according to the invention or a composition or combination comprising said compound of structure I is used to prevent, reduce and/or inhibit the synthesis of viral proteins in an animal or human infected by a virus as described in the present application.
  • viral proteins refers to at least one protein of the virus, in particular to at least one structural protein of the virus.
  • the viral proteins whose synthesis can be prevented, slowed, reduced and/or inhibited under the effect of the active ingredients according to the invention, in particular under the effect of the compound(s) of structure I according to the invention, include in particular the envelope, capsid, nucleocapsid proteins, etc., especially for the lentiviruses, the proteins Gag, Pol and Env.
  • the prevention or inhibition of the synthesis of viral proteins can be partial, or total, or partial for some of the viral proteins and total for the remainder of the viral proteins.
  • the expression “prevent or inhibit the synthesis of viral proteins” means that, under the effect of one or more active substance(s) according to the invention, in particular under the effect of one or more compound(s) of structure I according to the invention, one or more viral proteins are synthesized in a smaller quantity in the host cell, and are therefore present in a smaller quantity in the host cell or in the cell supernatant, as compared with the synthesis of the same viral proteins in the absence of said active substance(s).
  • the prevention or inhibition of the synthesis of viral proteins is total, the viral protein(s) is(are) not synthesized in a detectable manner.
  • the prevention or inhibition of protein synthesis can be evaluated, for example, by immunotransfer (Western blot), using specific antibodies directed against said viral proteins, as described in Example B6 and FIG. 6 .
  • the compound of structure I according to the invention or a composition or combination comprising said compound can further be used for preventing and/or inhibiting both (i) viral replication, in particular viral protein synthesis, and (ii) the increase in cell death, in particular the increase in the death of the T lymphocytes and more particularly of the CD4+ T cells, induced by a virus as described in the present application, in an animal or human infected by said virus.
  • the compound(s) of structure I according to the invention or a composition or combination comprising said compound(s) can be used in particular in the treatment or prophylaxis of a viral infection associated with an increase in cell death, in particular an increase in the death of the cells of the immune system and/or of the neuronal cells and/or of the epithelial cells, in an animal or human infected by said virus.
  • the invention is directed more particularly towards viral infections correlated with an increase in the cell death of the T cells, and in particular the CD4+ T cells, in an animal or human infected by a virus, in particular infections by the HIV viruses.
  • an “increase in cell death” or an “increase in apoptosis” within the scope of the present application means that the percentage cell death is greater than the percentage normally observed in the cell model in question.
  • the percentage cell death is greater than 1.7% (background noise observed according to Khan et al., 1998).
  • the percentage cell death is greater than 8% (background noise normally observed).
  • cell death or apoptosis increases by at least 10%, at least 20% or at least 40%, or even more.
  • TUNEL terminal deoxyribonucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end labelling
  • a viral infection associated with an increase in cell death and in particular “a viral infection associated with an increase in apoptosis” is understood as meaning an infection which is generally accompanied, in the more or less long term, by an increase in cell death and in particular in apoptosis.
  • the increase can be the direct and/or indirect result of contamination by a virus as described in the present application.
  • Prevention or inhibition of the increase in cell death or apoptosis can be partial or total.
  • the expression “prevent and/or inhibit the increase in cell death” or “prevent and/or inhibit the increase in apoptosis” means that, under the effect of one or more active substance(s) according to the invention, in particular under the effect of one or more caspase inhibitor(s) according to the invention, the number of dead cells or the number of apoptotic cells in the host organism or in certain tissues or for certain particular cell types of the host organism is reduced relative to the number observed in the absence of said active substance(s).
  • Cell death is reduced preferably by at least 10%, more preferably at least 30% and yet more preferably at least 50%.
  • the compound of structure I according to the invention can be prepared in the form of a pharmaceutical composition further comprising one or more carrier(s), diluent(s) and/or adjuvant(s) or a combination thereof, as well as other active substances.
  • a pharmaceutical composition further comprising one or more carrier(s), diluent(s) and/or adjuvant(s) or a combination thereof, as well as other active substances.
  • carrier(s) diluent(s) and/or adjuvant(s) or a combination thereof, as well as other active substances.
  • diluent(s) and/or adjuvant(s) or a combination thereof as well as other active substances.
  • an injectable administration there can be chosen especially a formulation in an aqueous, non-aqueous or isotonic solution.
  • the term “carrier” denotes any substrate (that is to say anything which is able to transport at least one active ingredient) which does not interfere with the efficacy of the biological activity of the active substances (in particular the compound(s) of structure I).
  • the carriers used can be, for example, water, a saline solution, serum albumin, a Ringer solution, polyethylene glycol, water-miscible solvents, sugars, binders, excipients, pigments, vegetable or mineral oils, water-soluble polymers, surface-active agents, thickening or gelling agents, cosmetic agents, solubilizing agents, stabilizing agents, preservatives, alkalinizing or acidifying agents or a combination thereof.
  • the formulation of such carriers in the form of a pharmaceutical composition is described especially in “Remington's Pharmaceutical Sciences”, 18th edition, Mack Publishing Company, Easton, Pa.
  • the term “diluent” means a diluting agent and includes soluble diluents and insoluble diluents. There is generally used an insoluble diluent when the active ingredient is soluble and a soluble diluent when the active ingredient is insoluble.
  • An “insoluble” active ingredient can be completely insoluble in an aqueous medium or can have limited solubility (that is to say a solubility of less than 10 mg/ml in 250 ml of water at a pH of from 1.0 to 7.5) in an aqueous medium.
  • insoluble diluents examples include microcrystalline cellulose, silicified microcrystalline cellulose, hydroxymethylcellulose, dicalcium phosphate, calcium carbonate, calcium sulfate, magnesium carbonate, tricalcium phosphate, etc.
  • soluble diluents include mannitol, glucose, sorbitol, maltose, dextrates, dextrins, dextrose, etc.
  • the adjuvants which can be used within the scope of the invention are in particular nucleic acids, peptidoglycans, carbohydrates, peptides, cytokines, hormones or other small molecules.
  • Said adjuvants that are used can be, for example, adjuvants of the non-methylated CpG dinucleotide (CpG) family, adjuvants of the poly IC family and adjuvants of the monophosphoryl lipid A (MPL) family or an analogue thereof.
  • CpG non-methylated CpG dinucleotide
  • MPL monophosphoryl lipid A
  • the carrier(s) or diluent(s) or combinations thereof used in the invention are pharmaceutically acceptable substances or a combination of pharmaceutically acceptable substances.
  • a substance or a combination of substances is said to be “pharmaceutically acceptable” when it is suitable for administration to a living being (for example a human or animal) for therapeutic or prophylactic purposes. It is therefore preferably non-toxic for the host to which it is administered.
  • administration and “administer” as used in the present application include any administration, whatever the chosen route of administration.
  • the routes of administration and the dosages vary according to a variety of parameters, for example according to the condition of the patient, the type of infection and the severity of the infection to be treated, or according to the compound(s) of structure I and the other antiviral agents used.
  • the compound of structure I according to the invention, the composition according to the invention (in particular the antiviral composition according to the invention) and the constituents of the combination according to the invention can especially be administered to an animal or human in dry form, in solid form (in particular tablet, powder, gelatin capsule, pill, granules, suppository, polymer capsule or compressed tablet, and more precisely accelerated release tablet, enteric-coated tablet or sustained release tablet), in gel form or in the form of a solution or liquid suspension (in particular syrup, injectable, infusible or drinkable solution, microvesicles, liposomes).
  • the compounds can also be in the form of doses in dry form (powder, lyophilisate, etc.) for reconstitution at the time of use using a suitable diluent.
  • the composition according to the invention in particular the antiviral composition of the invention
  • the constituents of the combination of the invention can be administered by the enteral, parenteral (intravenous, intramuscular or subcutaneous), transcutaneous (or transdermal or percutaneous), cutaneous, oral, mucosal, in particular transmucous-buccal, nasal, ophthalmic, otological (in the ear), oesophageal, vaginal or rectal route, or alternatively by the intragastric, intracardiac, intraperitoneal, intrapulmonary or intratracheal routes.
  • the compound of structure I, the composition of the invention or the constituents of the combination of the invention can be packaged for administration in the form of a single dose (monodose) or a multiple dose (multidose).
  • a single dose monodose
  • multidose multiple dose
  • the amount of active ingredient administered to an animal or human is a therapeutically effective amount.
  • a “therapeutically effective amount” is an amount sufficient to obtain a significant effect and in particular to bring a significant benefit to a human or animal within the scope of an administration for prophylaxis or treatment as defined in the present application.
  • a therapeutically effective amount is also an amount for which the beneficial effects outweigh any toxic or harmful effect of the active ingredient(s). Such an amount can correspond to an amount sufficient to significantly inhibit viral replication or to bring about the disappearance, reduction or improvement of any existing infection caused by a virus.
  • the therapeutically effective amount varies according to factors such as the state of infection and the age, sex or weight of the animal or human individual. The dosage regimens can be adjusted in order to obtain an optimum therapeutic effect.
  • a therapeutically effective amount of compound of structure I according to the invention can be from 100 to 300 mg/day, administered in from 1 to 3 doses.
  • the present invention relates also to the use of one or more compound(s) of structure I, in particular the use of the compound Q-VD-OPh, in association with other antiviral agents, in particular other antiretroviral agents, in the prophylaxis and/or treatment of a viral infection.
  • antiviral agents there may be mentioned, in connection with infection due to HIV, the combined antiretroviral drugs within the scope of highly active antiretroviral therapy (or “HAART”).
  • composition according to the invention further comprises at least one other antiviral agent.
  • the present invention therefore relates also to a novel antiviral composition
  • a novel antiviral composition comprising, consisting essentially of or consisting of:
  • the compound of structure I can therefore be used in association with an antiviral agent or a plurality of antiviral agents, in particular at least two other antiviral agents.
  • Said other antiviral agent or agents can in particular be antiretroviral agents.
  • antiviral and antiretroviral agents which can be used within the scope of the present application include in particular:
  • said other antiviral agent or agents consist(s) of at least one transcriptase inhibitor and/or at least one viral protease inhibitor.
  • the antiviral composition according to the invention comprises, consists essentially of or consists of:
  • transcriptase inhibitor as used in the present application includes in particular the nucleoside analogues, the non-nucleoside analogues and the nucleotide analogues of reverse transcriptase.
  • the transcriptase inhibitor is a reverse transcriptase inhibitor, in particular an HIV virus reverse transcriptase inhibitor, and more particularly a reverse transcriptase inhibitor selected from the group constituted by:
  • one of the transcriptase inhibitors used is AZT.
  • protease inhibitor as used in the present application includes in particular peptidomimetic molecules and molecules of the non-peptide type.
  • “Peptidomimetic molecules” are peptides which mimic the natural enzyme substrate and fix to the protease substrate binding sites, preventing cleavage of the protein precursors (for example Gag and Gag-Pol for HIV or SIV), which leads to the production of defective and non-infectious viral particles.
  • the viral protease inhibitor is a protease inhibitor of an HIV virus and in particular a viral protease inhibitor selected from the group constituted by the following peptidomimetic molecules: Indinavir or IDV, Nelfinavir or NLFN, Saquinavir or SQN, Ritonavir or RTN, Amprenavir, Lopinavir.
  • a viral protease inhibitor selected from the group constituted by the following peptidomimetic molecules: Indinavir or IDV, Nelfinavir or NLFN, Saquinavir or SQN, Ritonavir or RTN, Amprenavir, Lopinavir.
  • one of the HIV viral protease inhibitors used is Indinavir.
  • At least one of the other antiviral agents according to the invention is a fusion inhibitor, in particular an HIV virus fusion inhibitor, for example enfuvirtide.
  • a “fusion inhibitor” is understood as being an inhibitor which acts in the first stage of replication of the virus by preventing fusion between the viral envelope and the cell membrane, for example by competitive inhibition.
  • said antiviral composition can further comprise one or more carrier(s), diluent(s) and/or adjuvant(s) or a combination thereof as defined in the present application.
  • At least two compounds of the antiviral composition or of the combination according to the invention act in “synergy”. This means that it is possible by means of said antiviral composition or said combination to obtain a prophylactic or therapeutic effect that is superior to the sum of the individual effects of each of the compounds acting in synergy.
  • the compound(s) of structure I and at least one of the other antiviral agents act in synergy and, in particular, the compound(s) of structure I act(s) in synergy with at least one of the other antiviral agents.
  • the results presented in the present invention show that a compound such as Q-VD-OPh is capable of acting in synergy with other antiviral agents, and in particular with AZT and with Indinavir, to inhibit viral replication and to inhibit the death of the CD4+ T lymphocytes induced by the viral infection.
  • a compound of structure I in particular the use of the compound Q-VD-OPh, or of a composition or combination comprising such a compound can therefore enable a treatment based on one or more other antiviral agents, in particular an antiviral treatment that is not very effective against HIV or SIV viruses, to be improved or potentiated.
  • potentiate means that the use of one or more compounds of structure I according to the invention makes it possible to obtain a prophylactic or therapeutic effect that is superior to the prophylactic or therapeutic effect obtained using said other antiviral agent(s) alone or in combination with other medicament regimes.
  • the use of one or more compounds of structure I can also allow the doses of other antiviral agents that are used to be reduced without reducing the efficacy of the treatment, and even while increasing the efficacy of the treatment.
  • Another aspect of the present invention relates, therefore, to the use of one or more compound(s) of structure I, in particular the use of the compound Q-VD-OPh, in the production of a medicament for potentiating, for increasing a prophylactic or therapeutic effect of one or more other antiviral agents as defined in the present application and/or for reducing the amount of the other antiviral agents administered to a human or animal.
  • the present invention relates also to a compound of structure I, in particular the compound Q-VD-OPh, for use in potentiating, in increasing a prophylactic or therapeutic effect of one or more other antiviral agents as defined in the present application and/or in reducing the amount of the other antiviral agents administered to a human or animal.
  • the active ingredients are combined in a combination (or kit) for use in an antiviral therapy.
  • the present invention relates also to a combination (or kit) comprising, consisting essentially of or consisting of:
  • kit refers to the association, in the posology of a treatment intended for a human or animal infected by a virus, of at least two compounds suitable for use in an antiviral treatment in an animal or human:
  • Constituents (i) and (ii) form a functional unit by virtue of a common indication, which is the implementation of an antiviral treatment.
  • the combination can also comprise a plurality of compounds of structure I, for example 2, 3 or 4 or more, and/or a plurality of other antiviral agents, in particular 2, 3, 4 or more.
  • Such a combined therapy is intended most particularly for the prophylaxis and/or treatment of viral infections in a human or animal infected by a virus as defined in the present application.
  • compounds (i) and (ii) of said combination are present in two distinct compositions. “Present in two distinct compositions” is understood as meaning that said compounds are physically separate. They are then employed, administered separately, without prior mixing, in several (at least two) dosage forms (for example two distinct capsules). Said combination therefore corresponds to a presentation of the compound(s) (i) on the one hand and of the compound(s) (ii) on the other hand, in distinct compositions. Because compound(s) (i) is(are) not mixed with compound(s) (ii), the different compounds (i) and (ii) are not chemically modified and can consequently be administered as described in the notice(s) of compliance (AMM) covering the compound(s).
  • AAM notice(s) of compliance
  • compound (i) and compounds (ii) are administered sequentially in terms of time, the sequence of administration is not important, it being possible for administration of compound(s) (i) to precede or follow administration of compound(s) (ii).
  • compound (i) or at least one of compounds (i) is administered before compound (ii) or at least one of compounds (ii) is administered.
  • compound (ii) or at least one of compounds (ii) can be administered before compound (i) or at least one of compounds (i) is administered.
  • sequential administration means that said or one of said compounds (i) and said or one of said compounds (ii) of the combination or kit according to the invention are administered not simultaneously but separately in terms of time, one after the other.
  • precede or “preceding” is used when a compound (or a plurality of compounds) of the combination or kit according to the invention is administered a few minutes or several hours, or even several days, prior to administration of the other compound(s) of said combination or kit.
  • follow or “following” is used when a compound (or a plurality of compounds) of the combination or kit according to the invention is administered a few minutes or several hours, or even several days, after administration of the other compound(s) of said combination or kit.
  • compounds (i) and (ii) of the combination or kit according to the invention are formulated for administration at an interval of one or several hours, preferably a 1-, 2-, 3- or 4-hour interval, more preferably a 1- or 2-hour interval, yet more preferably a 1-hour interval.
  • the compound(s) (i) and the compound(s) (ii) of the combination can be formulated to facilitate their ingestion and, in particular, can be formulated with one or more carrier(s), diluent(s) or adjuvant(s) as defined above, or a combination thereof.
  • the compound(s) (i) and the compound(s) (ii) of the combination or kit according to the invention can be administered by the same route of administration or, on the other hand, by distinct routes of administration.
  • the possible galenical forms and routes of administration are those described above.
  • said other antiviral agent(s) consist(s) of at least one transcriptase, especially reverse transcriptase, inhibitor as defined in the present application and/or at least one viral protease inhibitor as defined in the present application.
  • composition according to the invention comprises:
  • the present invention relates also to an antiviral composition or a combination according to the invention for use as a medicament, in particular as an antiviral agent and more particularly as an antiretroviral agent. More precisely, said antiviral composition or said combination can be used in the prophylaxis and/or treatment of a viral infection, in particular an infection caused by a virus as defined in the present application, and more particularly for inhibiting viral replication, in a mammal or human.
  • the present invention relates also to the use of an antiviral composition or of a combination according to the invention in the production of a pharmaceutical composition for the prophylaxis and/or treatment of a viral infection, in particular an infection caused by a virus as defined in the present application, in a mammal or human.
  • the invention relates also to a method of treating an animal or human infected by a virus as described in the present application, said method comprising at least one step of administration of the compound(s) of structure I according to the invention, of the antiviral composition according to the invention or of the constituents of the combination according to the invention.
  • Said treatment method is, in particular, suitable for and intended for use in the prophylaxis and/or treatment of a viral infection, in particular in a human or animal infected by a virus as defined in the present application.
  • said treatment method can be used to prevent and/or inhibit viral replication in an animal or human infected by a virus.
  • said treatment method can be used to prevent and/or inhibit the increase in cell death in an animal or human infected by a virus, in particular the increase in the death of the T lymphocytes and more particularly the increase in the death of the CD4 T lymphocytes.
  • the treatment method according to the invention is considered to have achieved the expected therapeutic effect if it permits a reduction of at least 10%, preferably 30%, and more preferably at least 50%, in viral replication in the treated animal or human.
  • the therapeutic effect can also be defined in relation to the clinical standards developed for measuring the beneficial effects of medicaments on HIV infection.
  • a drug has a beneficial effect if it halves the plasma viral load in humans.
  • a drug has a super-beneficial effect if it divides the plasma viral load in humans by 100.
  • FIG. 1 Immunoblot (Western blot) showing the effectiveness of Q-VD-OPh in inhibiting activation of caspase-3 and -8.
  • CD4 + T lymphocytes were or were not infected by the HIV-1 virus (incubation: 2 hours) and then stimulated by Concanavalin A and IL-2 (incubation: 2 hours). After stimulation, the inhibitor Q-VD-OPh was added to the cell culture at a final concentration of 10 ⁇ M and then also added 36 hours after infection (d3) and 96 hours after infection (d4). The immunoblot was carried out on the 6th day post-infection. Caspase-3 and -8 were detected using the anticaspase antibodies indicated above.
  • NI control cells (CD4 + T cells not infected by HIV-1 and not treated with Q-VD-OPh); HIV: CD4 + T cells infected by HIV-1 but not treated with Q-VD-OPh; HIV+QVD: CD4 + T cells infected by HIV-1 and then cultivated in the presence of 10 ⁇ M of Q-VD-OPh. Actin serves as the control for the protein load of the gel.
  • the molecular weight marker RPN 800 (Amersham) was used.
  • FIG. 2 Analysis of the CD4+ T lymphocytes by flow cytometry on the 5th day after infection by HIV-1 and after stimulation by Concanavalin A and IL-2.
  • NI uninfected CD4+ T lymphocytes
  • HIV CD4+ T lymphocytes infected by HIV-1
  • HIV Q-VD-OPh CD4+ T lymphocytes infected by HIV-1 (incubation: 2 hours), activated by ConA and IL2 (incubation 2 hours) and then incubated with Q-VD-OPh (10 ⁇ M final); Q-VD-OPh is added 36 hours (day 3) and 96 hours (day 4) after the start of the infection.
  • FIG. 3 Immunoblot (Western blot) showing the effect of Q-VD-OPh on mitochondrial damage resulting from viral replication.
  • Primary CD4+ T cells were infected with HIV-Lai and stimulated with a ConA/IL-2 cocktail and then treated or not treated with 10 ⁇ M of Q-VD-OPh (QVD) and/or 10 ⁇ M of pepstatin A (PA) immediately after stimulation and then 36 hours (day 3) and 96 hours (day 4) after infection. On the 5th day post-infection, the cells were fractionated into two parts: the membrane fraction and the cytosol fraction.
  • QVD Q-VD-OPh
  • PA pepstatin A
  • Cytochrome c Cytochrome c
  • Smac/Diablo Endonuclease G
  • EndoG Endonuclease G
  • FIG. 4 Graphic representation showing the effect of Q-VD-OPh on replication of the HIV-1 virus.
  • A Determination of the percentage of CD4+ T lymphocytes infected by HIV-1 by flow cytometry, after intracellular labelling of the p24 viral antigen.
  • B ELISA assay of the p24 viral antigen in the culture supernatants. All the cells were stimulated by Con A and IL2 within 24 hours of infection. The parameters were measured on the 6th day post-infection.
  • NI uninfected CD4+ T lymphocytes
  • HIV CD4+ T lymphocytes infected by HIV-1
  • HIV+QVD and HIV+PA+QVD CD4+ T lymphocytes infected by HIV-1, to which there were administered, on the 3rd day post-infection and then every day, Q-VD-OPh (QVD) or Q-VD-OPh (QVD) and pepstatin A (PA), respectively.
  • FIG. 5 The time at which Q-VD-OPh is administered to the CD4+ T lymphocytes influences the inhibition of cell death and the inhibition of viral replication.
  • CD4+ T lymphocytes were or were not infected with HIV-Lai and stimulated with a ConA/IL2 cocktail and then treated or not treated with 10 ⁇ M of Q-VD-OPh and/or 10 ⁇ M of pepstatin A. There were determined, by flow cytometry, the percentage of CD4+ T lymphocytes infected by HIV after intracellular labelling of the p24 antigen (A) and the percentage of dead CD4+ T lymphocytes (B) on the 5th day after infection by HIV-1. The parameters were measured on the 5th day post-infection.
  • NI CD4+ T lymphocytes not infected by HIV-1
  • HIV CD4+ T lymphocytes infected by HIV-1
  • Q-VD CD4+ T lymphocytes infected by HIV-1, to which there were administered Q-VD-OPh and pepstatin A (PA);
  • Q-VD-OPh and PA were administered between 1 and 2 hours before infection by HIV-1 and stimulation by Concanavalin A and IL-2 and then on d3 and d4 post-infection, at a final concentration of 10 ⁇ M.
  • Q-VD-OPh and PA were administered immediately after infection by HIV-1 and on d3 and d4 post-infection at different final concentrations (0.5; 1; 2; 5; 10 and 20 ⁇ M).
  • FIG. 6 Immunoblot (Western blot) showing the inhibitory effect of Q-VD-OPh on the expression of a group of HIV-1 proteins in primary CD4+ cells.
  • Protein extracts prepared on the 6th day of culturing from uninfected CD4+ T lymphocytes (NI) or CD4+ T lymphocytes infected by the HIV-1 virus and then cultivated in the absence of Q-VD-OPh (HIV) or in the presence of Q-VD-OPh (HIV+Q-VD-OPh) were fractionated into three parts: the cytosol fractions (cytosol), the soluble membrane fractions (soluble) and the insoluble membrane fractions (insoluble).
  • Q-VD-OPh was added at a final concentration of 10 ⁇ M, immediately after infection and then 36 hours (d3) and 96 hours (d4) post-infection.
  • the proteins specific to HIV were detected using a mixture of sera from HIV+patients. They are indicated on the right of the immunoblot.
  • the molecular weight marker RPN 800 (Amersham) was used.
  • FIG. 7 Graphic representation showing the effect of Q-VD-OPh on primary HIV-1 strains.
  • the CD4+ T lymphocytes were stimulated with concanavalin A and IL2 (stimulation being carried out before or during administration of Q-VD-OPh), and Q-VD-OPh was added at a final concentration of 10 ⁇ M, immediately after infection and then 36 hours (d3) and 96 hours (d4) post-infection.
  • CD4+ T lymphocytes infected with the HIV-1Lai virus or with the serum of a chronic HIV+ patient (strain with X4/R5 dual tropism) and then cultivated in the absence or presence (+Q-VD) of Q-VD-OPh.
  • the percentage of CD4+ cells infected by HIV was determined after intracellular labelling of the p24 viral antigen on the 5th day post-infection in the case of the HIV-Lai virus and on the 6th day post-infection in the case of the serum.
  • PE phycoerythrin, fluorochrome (emission at 578 nm) coupled to the anti-p24 antibody.
  • FIG. 8 Graphic representation showing the inhibitory effect of Q-VD-OPh on replication of the SIVmac251 virus and the formation of syncitia.
  • the cell line CEMx174 was infected with 200 AID50 (infectious dose necessary for 50% of the animals to be infected) of the strain SIVmac251. Two hours after infection, the cell line was treated with different concentrations of inhibitor Q-VD-OPh (final concentration of 20, 10 or 2.5 ⁇ M) or was not treated (0 ⁇ M). On the 4th and 5th days post-infection, viral production in the culture supernatant was evaluated by RT-PCR (Taqman) and the number of syncytia was evaluated using an optical microscope.
  • FIG. 9 Graphic representation showing a synergistic effect of Q-VD-OPh with AZT and Indinavir.
  • Primary CD4+ T cells infected by the HIV-Lai virus and then stimulated with concanavalin A and IL-2 were treated 96 hours after infection with different concentrations of Q-VD-OPh (0, 0.1, 1 and 10 ⁇ M) in the absence or presence of azidothymidine (AZT; 0.1 ⁇ M) or Indinavir (IND; 1 ⁇ M). Inhibition of cell death was quantified by flow cytometry on the 5th day post-infection. It is expressed as follows:
  • FIG. 10 Analysis by flow cytometry of the fall in the mitochondrial transmembrane potential (% ⁇ m low) starting from Jurkat cells incubated in the absence or presence of different concentrations of anti-CD95 (A) and in the absence or presence of 0.25 ⁇ g/ml of anti-CD95 and of different caspase inhibitors (B).
  • A concentration of anti-CD95
  • B concentration of 0.25 ⁇ g/ml of anti-CD95 and of different caspase inhibitors
  • C Analysis by immunoblot of Jurkat cell extracts treated in the presence or absence of anti-CD95 and of different caspase inhibitors.
  • FIG. 11 Analysis by flow cytometry of the internal viral protein p24 (A) and of the fall in the mitochondrial transmembrane potential (% ⁇ m low; B) on the 5th (d5) and 7th (d7) day post-infection in primary CD4+ T cells infected by the strain HIV-Lai, after stimulation by Concanavalin A and IL-2 and in the presence or absence of 10 ⁇ M of different caspase inhibitors.
  • FIG. 12 Analysis by immunoblot of the quantity of HIV viral proteins produced from extracts of primary CD4 T cells infected by the strain HIV-Lai in the presence or absence of different caspase inhibitors.
  • FIG. 13 Analysis by flow cytometry of lymphocyte proliferation after 4 and 5 days' stimulation by 1 ⁇ g/m1 of anti-CD-3, in the presence or absence of HIV antiproteases or of QVD-OPH.
  • FIG. 14 Analysis of the fall in the mitochondrial transmembrane potential (% ⁇ m low) by flow cytometry starting from cells stimulated by 1 ⁇ g/ml of anti-CD-3 in the presence or absence of different HIV antiproteases and of QVD-OPH.
  • FIG. 15 Analysis of the fall in the mitochondrial transmembrane potential (% ⁇ m low) by flow cytometry in monocytes and lymphocytes in the presence of different HIV antiproteases or of QVD-OPH.
  • cytofluorometry anti-p24 monoclonal antibody, clone KC57-RD1 (Beckman coulter).
  • Cathepsin D inhibitor pepstatin A (Sigma).
  • Reverse transcriptase inhibitor didanosine (or ddl) or Videx EC® (Bristol-Myers Squibb).
  • Peripheral blood mononuclear cells obtained from healthy volunteers were isolated on Ficoll strains (Petit et al., 2002). The majority of the adherent cells were eliminated by incubation in plastics culture dishes.
  • the circulating CD4 + cells were selected negatively using a CD4 + cell isolation kit, in accordance with the supplier's instructions (MACS, CD4 T cell isolation kit II; Miltenyi Biotech, Paris, France). The purity of the isolated CD4 + population, determined by flow cytometry, was ⁇ 96%. Monocytes recovered from the adherent dishes were added to the purified CD4 + cells in a final percentage of 6%.
  • composition of the culture medium used is as follows: RPMI 1640, 10% foetal calf serum, 2 mM glutamine, 1 mM pyruvate, 50 units/ml of penicillin and 50 ⁇ g/ml of streptomycin.
  • the CD4 + cells were incubated for 2 hours at 37° C. in the presence of 10 ng/ml of HIV-1 virus of strain Lai or 50 ng/ml of primary strains of the HIV-1 virus. After 2 washings, the cells were resuspended in a complete medium in the presence of 5 ⁇ g/ml of concanavalin A (Con A) and 10 mg/ml of interleukin 2 (IL 2).
  • Con A concanavalin A
  • IL 2 interleukin 2
  • the HIV p24 antigen was measured in the cell culture supernatants by an ELISA test (Abbott).
  • the intracellular p24 antigen was determined by flow cytometry with the aid of a specific antibody (KC57, Coulter Corp) and after permeabilization of the cells using the permeabilization reagent Intraprep (Coulter Corp.).
  • the CD4 + cells were labelled for 15 minutes at 37° C. with 40 nM of DIOC 6 (3-3′-diethyloxacarbocyanine).
  • the dead cells exhibit a reduction in labelling intensity.
  • the size and morphometry were also determined.
  • the apoptotic/dead cells were counted by white-light microscopy, on the basis of abnormal cell morphology and/or the absorption of trypan blue.
  • the cytosol and mitochondrial fractions were obtained by the subcellular fractionation technique based on selective permeabilization by digitonin according to Foghsgaard et al. ⁇ Foghsgaard, 2001 ⁇ . Briefly, 10 7 cells were washed twice in PBS and incubated for 5 minutes on ice with 100 ⁇ l of extraction buffer (35 ⁇ g/ml digitonin, 250 mM sucrose, 137 mM NaCl, 70 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 , 2 mM EDTA, pH 7.2) supplemented with a protease inhibitor cocktail (“Complete” from Roche Applied Science, Penzberg, Germany).
  • extraction buffer 35 ⁇ g/ml digitonin, 250 mM sucrose, 137 mM NaCl, 70 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4
  • the extracts were centrifuged at 300 g for 5 minutes, and the resulting supernatant was recentrifuged again at 10,000 g for 10 minutes at 4° C. in order to remove the debris.
  • the final supernatant, called the cytosol fraction was stored at ⁇ 80° C.
  • the pellet was dissolved in 100 ⁇ l of mitochondrial lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 0.5% NP40, 0.2% Triton X100) supplemented with “Complete” protease inhibitor cocktail from Roche, for 30 minutes on ice at 4° C., followed by centrifugation at 10,000 g for 30 minutes at 4° C. in order to obtain the so-called “soluble” mitochondrial fraction.
  • the protein concentration of the cytosol and mitochondrial fractions was determined by the bicinchoninic acid (BCA) method (Bio-Rad).
  • Q-VD-OPh The effectiveness of Q-VD-OPh in inhibiting activation of caspase-3 and -8 was analyzed by immunoblot (Western blot).
  • CD4 + T lymphocytes in culture were infected by the HIV-1 virus and then stimulated, 2 hours after infection, by Concanavalin A and IL-2. Following stimulation, 10 ⁇ M of inhibitor Q-VD-OPh were added to the cell culture.
  • Q-VD-OPh was added again 36 hours (3 days) and then 96 hours (4 days) after infection, still at a final concentration of 10 ⁇ M. Protein extraction and immunoblot were carried out on the 6th day post-infection.
  • caspase-3 and -8 are substantially in forms p32 and p55, respectively, which correspond to the inactive forms (proforms) of caspase-3 and -8.
  • the intermediate forms p20 for caspase-3 and p44, p26 and p20 for caspase-8 are also found (Alam et al., 1999; Petit et al., 2002).
  • the inventors analyzed, by immunotransfer (Western blot), the effect of Q-VD-OPh on the release of apoptogenic mitochondrial factors caused by viral replication.
  • Primary CD4+ T cells were infected with the HIV-Lai virus and then stimulated with a concanavalin A/IL-2 cocktail before being treated with Q-VD-OPh (10 ⁇ M) and/or pepstatin A (10 ⁇ M).
  • the cells were fractionated into two parts: (i) the mitochondrial membrane fraction and (ii) the cytosol fraction, which may contain mitochondrial factors released following permeabilization of the mitochondrial membrane caused by the viral infection.
  • FIG. 3 shows the presence of these apoptogenic factors in the cytosol fraction of the cells infected by HIV-Lai, whereas in the uninfected cells they are located in the mitochondrial membrane fraction, which is the indicator of mitochondrial damage. This suggests that the massive death of the CD4+ T cells observed following an HIV infection is the result of a mechanism of cell death which passes through a loss of permeability of the mitochondrial membrane and a spreading of apoptogenic factors into the cytosol.
  • the replication of the HIV-1 virus in the presence or absence of Q-VD-OPh was evaluated by quantification of the number of TCD4+ lymphocytes expressing the p24 antigen in CD4+ T lymphocytes infected by HIV and stimulated by ConA and IL-2.
  • Analysis of the percentage of CD4+ T lymphocytes infected by HIV-1 on the 5th and 6th days post-infection ( FIGS. 2C and 4A , respectively) and of the amount of the p24 viral antigen in the culture supernatants on the 6th day post-infection ( FIG. 4B ) show that the compound Q-VD-OPh reduces viral replication by more than 75%.
  • the inhibition of viral replication is even stronger when the CD4+ T lymphocytes are treated both with the compound Q-VD-OPh and with another protease inhibitor, pepstatin A (pepsin inhibitor).
  • FIGS. 2C and 4A show the count of cells expressing the p24 viral antigen by immunological labelling and flow cytometry. Five days after infection, 72.6% of the cells express the viral antigen and are therefore infected. If the infection is followed by the addition of Q-VD-OPh, only 18% of the cells are infected five days after infection.
  • Q-VD-OPh was administered to CD4+ T lymphocytes in culture either before infection with HIV-1 or after. In each case there was determined, by flow cytometry, on the 5th day post-infection, the percentage of CD4+ T lymphocytes infected by the virus by intracellular labelling of the p24 antigen ( FIG. 7A ) and the percentage of dead CD4+ lymphocytes ( FIG. 7B ).
  • the inhibitor Q-VD-OPh may be used not only to treat a viral infection but also prophylactically, in order to prevent a viral infection.
  • Q-VD-OPh Inhibits the Expression of a Group of HIV-1 Proteins in Primary CD4+ T Cells.
  • the inventors analyzed the expression, on the 6th day post-infection, of the HIV-1 proteins in the cytosol fractions, the soluble membrane fractions and the insoluble membrane fractions of CD4+ T lymphocytes infected by the HIV-1 virus and then incubated in the presence or absence of the compound Q-VD-OPh.
  • the expression profile obtained shows that the inhibitor Q-VD-OPh drastically reduces the totality of HIV proteins expressed in the cytosol and in the membrane fractions of the primary CD4+ T lymphocytes.
  • the presence of inhibitors does not cause different compartmentalization of the proteins nor an accumulation of the proforms.
  • Q-VD-OPh therefore has an inhibitory effect for the expression of the totality of the viral genome but has no effect on intracellular protein traffic and therefore on the maturation of the proteins.
  • Viral replication was analyzed by flow cytometry in CD4+ T lymphocytes infected by the HIV-1 Lai virus or with the serum of a chronic HIV+ patient containing a primary strain with X4/R5 dual tropism.
  • the inventors further analyzed the replication of five primary HIV-1 isolates taken from HIV+ patients, of R5 tropism, in the absence or presence of the inhibitor Q-VD-OPh or of ddl, a reverse transcriptase inhibitor. It is noted that, for the five primary isolates, Q-VD-OPh and ddl have a similar effect, namely strong inhibition of viral replication (see FIG. 5C ).
  • the viral strains with R5 tropism are those which are found most commonly and have the characteristic of emerging early during the infection and of persisting throughout the evolution of the disease, whereas the viral strains with X4 tropism tend to be late strains.
  • the ability of Q-VD-OPh to inhibit viral replication more particularly of the viral strains with R5 tropism renders this molecule very interesting from a therapeutic point of view because it may be used to stop a viral infection at a very early stage.
  • the inventors analyzed the effect of Q-VD-OPh on replication of the SIVmac251 virus and on the formation of syncytia ( FIG. 8 ).
  • the cell line CEMx174 was infected with a strong dose of virus of the strain SIVmac251 (200 AID50), which corresponds to ten times the concentration used to infect monkeys.
  • Analysis of viral production in the culture supernatant by RT-PCR on the 4th and 5th days post-infection shows that replication of the SIVmac251 virus is inhibited in the presence of the inhibitor Q-VD-OPh, in a dose-dependent manner.
  • a high concentration of inhibitor (20 ⁇ M) is administered, viral replication is inhibited by more than 70%. Consequently, it appears that Q-VD-OPh inhibits replication of the HIV and SIV viruses in a similar manner.
  • syncytia a characteristic which would be linked to greater or lesser virulence, is likewise strongly inhibited under the effect of the inhibitor Q-VD-OPh.
  • a concentration of Q-VD-OPh equal to or greater than 10 ⁇ M is required to obtain a 70% reduction in the number of syncytia 5 days after infection and treatment.
  • Q-VD-OPh is a broad-spectrum viral replication inhibitor which allows not only HIV viruses but also SIV viruses to be blocked.
  • Q-VD-OPh Acts in Synergy with AZT and Indinavir to Inhibit Viral Replication and Death of the CD4 + T Lymphocytes.
  • Primary CD4+ T cells were infected by an HIV-Lai virus and then stimulated with concanavalin A and IL-2. The cells were then cultivated in the presence or absence of Q-VD-OPh (0.1, 1 or 10 ⁇ M) and in the presence or absence of AZT (0.1 ⁇ M) or Indinavir (1 ⁇ M). Where the drugs were added to the culture, they were added 96 hours (d3) after infection. Cell death was then quantified by flow cytometry on the 5th day post-infection.
  • FIG. 9 show that Q-VD-OPh, when used in combination with AZT or Indinavir, inhibits cell death resulting from viral infection much more strongly than Q-VD-OPh, AZT or Indinavir used alone. Consequently, Q-VD-OPh used in association with anti-HIV treatments for preventing cell death, which is a consequence of viral replication, gives rise to a synergistic effect.
  • the compound Q-VD-OPh is therefore of major interest for therapeutic use as an antiviral agent and in particular as an antiretroviral agent, and as an antilentiviral agent.
  • Q-VD-OPh may be an additional advantage allowing the immune response in respect of pathogenic agents to be restored in a more consistent manner.
  • Q-VD-OPh is capable of acting in synergy with other antiviral molecules such as AZT and Indinavir.
  • the cells were labelled with a fluorescent probe DIOC 6 (Molecular Probes, Invitrogen), at a concentration of 40 nM, and incubated for 15 minutes at 37° C.
  • Viral replication was evaluated by internal labelling of the p24 viral protein using an anti-p24-PE antibody (KC-57, Coulter Corp, Beckman).
  • the secondary antibodies coupled to peroxidase allows the proteins to be revealed by chemiluminescence (ECL, Amersham) using a CCD camera (G :Box-Chemi-XT16-SynGene).
  • the broad-spectrum caspase inhibitor Z-VAD-fmk (Calbiochem), the general caspase inhibitor: Q-VD-OPH, the caspase-8 inhibitor: Q-IETD-OPH, the caspase-3, -7 inhibitor: Q-DEVD-OPH and the caspase-9 inhibitor: Q-LEHD-OPH (MP Biomechanicalcals, France) were used.
  • the anti-CD95 antibody human Fas
  • the HIV antiproteases Saquinavir, Ritonavir and Indinavir are obtained from NIH.
  • the probe CFSE (carboxyfluorescein diacetate succinimidyl ester) used for the proliferation study was obtained from Molecular Probes (Invitrogen).
  • the PBMCs are incubated in the presence of 1 ⁇ M of CFSE for 7 minutes at 37° C.
  • the cells are taken up at 1.10 6 /ml and then placed in culture and activated by an anti-CD3 at 1 ⁇ g/ml (Immunotech).
  • Jurkat cells were incubated in the presence or absence of anti-CD95 at different concentrations in order to determine a dose-response curve for apoptosis. Death was evaluated by analyzing the fall in the mitochondrial transmembrane potential (% ⁇ m low) using the probe DIOC6, by flow cytometry ( FIG. 10A ). The same experiment was then conducted in the presence of 0.25 ⁇ g/ml of anti-CD95 and different caspase inhibitors. The apoptosis induced by anti-CD95 is expressed by the percentage ⁇ m low analyzed by flow cytometry ( FIG. 10B ).
  • a lymphocyte proliferation study was conducted with the fluorescent probe CFSE, which allows cell division to be monitored.
  • the PBMCs are stimulated with anti-CD3 at 1 ⁇ g/ml and incubated in the presence or absence of the HIV antiproteases Saquinavir, Ritonavir and Indinavir, at concentrations of 1 ⁇ M, 10 ⁇ M and 50 ⁇ M, as well as QVD-OPH at 10 ⁇ M, 50 ⁇ M and 100 ⁇ M.
  • Analysis of CFSE carried out after 4 and 5 days' stimulation shows, by flow cytometry, that the HIV antiproteases block the proliferation of lymphocytes at a dose of 50 ⁇ M.
  • QVD-OPH on the other hand, at the same concentrations, has no effect on lymphocyte proliferation ( FIG. 13 ).
  • the cell toxicity was evaluated by analysis of the fall in the mitochondrial transmembrane potential (% ⁇ m low) using the probe DIOC6, by flow cytometry.
  • the cells stimulated by anti-CD3 were analyzed in the same way on the day following activation. Accordingly, QVD-OPH, even at high concentrations (100 ⁇ M), has no effect on mitochondrial depolarization (compared with the control), whereas Indinavir and Saquinavir show a fall in ⁇ m of more than 70-80% at a dose of 50 ⁇ M ( FIG. 14 ).
  • PBMCs are incubated in the presence of the different HIV antiproteases Saquinavir, Ritonavir and Indinavir, at concentrations of 1 ⁇ M, 10 ⁇ M and 50 ⁇ M, as well as QVD-OPH at 10 ⁇ M, 50 ⁇ M and 100 ⁇ M.
  • the cell toxicity was evaluated by analysis of the fall in the mitochondrial transmembrane potential (% ⁇ m low) after 4 days' culture by analyzing the monocytes and lymphocytes.
  • the effect of QVD-OPH on mitochondrial depolarization remains minimal on one or other of the populations even at a concentration of 100 ⁇ M, while the HIV antiproteases, in particular Saquinavir, show depolarization of more than 90% ( FIG. 15A and B).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/740,790 2007-11-02 2008-10-31 Compounds for preventing or treating a viral infection Abandoned US20100298209A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0707722A FR2923160B1 (fr) 2007-11-02 2007-11-02 Composes destines a prevenir ou traiter une infection virale.
FR0707722 2007-11-02
PCT/FR2008/001538 WO2009092897A1 (fr) 2007-11-02 2008-10-31 Composes destines a prevenir ou traiter une infection virale

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001538 A-371-Of-International WO2009092897A1 (fr) 2007-11-02 2008-10-31 Composes destines a prevenir ou traiter une infection virale

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/921,998 Division US9056071B2 (en) 2007-11-02 2013-06-19 Compounds and methods for preventing or treating a viral infection

Publications (1)

Publication Number Publication Date
US20100298209A1 true US20100298209A1 (en) 2010-11-25

Family

ID=39323613

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/740,790 Abandoned US20100298209A1 (en) 2007-11-02 2008-10-31 Compounds for preventing or treating a viral infection
US13/921,998 Active US9056071B2 (en) 2007-11-02 2013-06-19 Compounds and methods for preventing or treating a viral infection
US14/713,477 Active US9833492B2 (en) 2007-11-02 2015-05-15 Combinations of a caspase inhibitor and an antiviral agent

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/921,998 Active US9056071B2 (en) 2007-11-02 2013-06-19 Compounds and methods for preventing or treating a viral infection
US14/713,477 Active US9833492B2 (en) 2007-11-02 2015-05-15 Combinations of a caspase inhibitor and an antiviral agent

Country Status (4)

Country Link
US (3) US20100298209A1 (fr)
EP (1) EP2214665B1 (fr)
FR (1) FR2923160B1 (fr)
WO (1) WO2009092897A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012157984A2 (fr) * 2011-05-19 2012-11-22 광주과학기술원 Nouveaux composés hétéroaromatiques et utilisation de ceux-ci
WO2021228846A1 (fr) * 2020-05-11 2021-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composé pour la prévention ou le traitement d'une infection virale

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115551536A (zh) * 2020-03-30 2022-12-30 约翰斯·霍普金斯大学 用于增强损伤修复以及治疗细菌和病毒感染的胱天蛋白酶抑制剂
WO2022197869A2 (fr) * 2021-03-16 2022-09-22 Amerimmune, Llc Traitement de maladies corrélées à l'expression de pannexine 1
WO2023139182A1 (fr) 2022-01-24 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Composé destiné à des fins d'utilisation dans la prévention et/ou le traitement d'une infection provoquée par le sars-cov-2

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US20020052323A1 (en) * 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
US6506555B1 (en) * 1998-06-11 2003-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of HIV protease inhibiting compounds
US20060275260A1 (en) * 2004-06-04 2006-12-07 Phillippe Riviere Use of imatinib to treat liver disorders and viral infections
US7553852B2 (en) * 2002-06-28 2009-06-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7612091B2 (en) * 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3002700B2 (ja) * 1990-08-29 2000-01-24 化研生薬株式会社 抗エイズウイルス剤
BR9814817A (pt) * 1997-10-10 2002-01-08 Cytovia Inc Inibidores de apoptose de dipeptìdio e o uso dos mesmos
US7247700B2 (en) * 2001-12-31 2007-07-24 Dana Farber Cancer Institute, Inc. BID polypeptides and methods of inducing apoptosis
CA2637843C (fr) * 2006-01-20 2014-12-30 Reneuron, Inc. Procede permettant d'ameliorer la proliferation cellulaire des cellules progenitrices pancreatiques dans une culture de cellules pancreatiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6506555B1 (en) * 1998-06-11 2003-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of HIV protease inhibiting compounds
US20020052323A1 (en) * 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
US7553852B2 (en) * 2002-06-28 2009-06-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7612091B2 (en) * 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20060275260A1 (en) * 2004-06-04 2006-12-07 Phillippe Riviere Use of imatinib to treat liver disorders and viral infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Avian flu from http://www.mayoclinic.com/health/bird-flu/DS00566/DSECTION=treatments-and-drugs, pp. 1-2. Accessed 8/9/12. *
Hep A from http://www.mayoclinic.com/health/hepatitis-a/DS00397/DSECTION=treatments-and-drugs, pp. 1-2. Accessed 8/9/12. *
Polio from http://www.mayoclinic.com/health/polio/DS00572/DSECTION=treatments-and-drugs, pp. 1-2. Accessed 8/9/12. *
SARS from http://www.nature.com/nature/focus/sars/sars3.html, pp. 1-4. Accessed 8/9/12. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012157984A2 (fr) * 2011-05-19 2012-11-22 광주과학기술원 Nouveaux composés hétéroaromatiques et utilisation de ceux-ci
WO2012157984A3 (fr) * 2011-05-19 2013-03-21 광주과학기술원 Nouveaux composés hétéroaromatiques et utilisation de ceux-ci
KR101348900B1 (ko) 2011-05-19 2014-01-07 광주과학기술원 신규한 헤테로방향족 화합물 및 이의 용도
WO2021228846A1 (fr) * 2020-05-11 2021-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composé pour la prévention ou le traitement d'une infection virale

Also Published As

Publication number Publication date
US9833492B2 (en) 2017-12-05
EP2214665B1 (fr) 2018-07-11
US20140031276A1 (en) 2014-01-30
EP2214665A1 (fr) 2010-08-11
US9056071B2 (en) 2015-06-16
FR2923160A1 (fr) 2009-05-08
WO2009092897A1 (fr) 2009-07-30
FR2923160B1 (fr) 2013-07-26
US20150246091A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
Liu et al. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
US9833492B2 (en) Combinations of a caspase inhibitor and an antiviral agent
Zhu et al. Broad-spectrum antiviral agents
Ashour et al. A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval
JP2009512716A (ja) Ｈｉｖ−１キャプシド構築の低分子阻害剤
Pereira et al. Anti-HIV drug development-an overview
Stefanidou et al. Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention
US20190032032A1 (en) Peptide having anti-viral effect and composition containing same
Vlahakis et al. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo
Herrera et al. Potential use of protease inhibitors as vaginal and colorectal microbicides
US20230158103A1 (en) Pld for use in combination in the treatment of coronavirus
US20230181560A1 (en) Compound for preventing or treating a viral infection
JP2009242247A (ja) ヒト免疫不全ウイルス感染阻害剤およびエイズの治療薬または予防薬
JP2004538334A (ja) Ｈｉｖ感染の治療に使用される薬剤とその成分と使用法
WO2011089166A1 (fr) Inhibiteurs du protéasome à base de semicarbazone pour traiter une infection par le vih et une infection par une hépatite
Rahman et al. Therapeutic approaches towards COVID-19: A critical insight
WO2021164689A1 (fr) Application de nelfinavir dans la préparation d'un médicament pour la prévention et le traitement d'une nouvelle pneumonie à coronavirus
EP2908821A1 (fr) Traitement de maladies virales et infectieuses en utilisant un inhibiteur de cbp/caténine
Verma In search of feasible interventions for the prevention and cure of novel coronavirus disease 2019
Bourinbaiar et al. Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro
Hassan et al. Pharmacologic agents for the management of COVID-19: a review
JP2009526824A (ja) インフルエンザウィルスでの感染の治療のための剤
Barroso et al. The effects of HIV and the antiretrovirals on the mitochondria
US20210378985A1 (en) Method and compound for the treatment of hepatitis c
Terekhov et al. DRUG DESIGN STRATEGIES FOR THE TREATMENT OF CORONAVIRUS INFECTION

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ESTAQUIER, JEROME;LAFORGE, MIREILLE;SENIK, ANNA;REEL/FRAME:024808/0719

Effective date: 20100716

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ESTAQUIER, JEROME;LAFORGE, MIREILLE;SENIK, ANNA;REEL/FRAME:024808/0719

Effective date: 20100716

Owner name: INSTITUT PASTEUR, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ESTAQUIER, JEROME;LAFORGE, MIREILLE;SENIK, ANNA;REEL/FRAME:024808/0719

Effective date: 20100716

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION